title: The impact of early intensive therapy on event-free survival (EFS) in children with acute myeloid leukemia (AML).
authors.forename: H
authors.initials: H
authors.lastname: Weinstein
authors.forename: Y
authors.initials: Y
authors.lastname: Ravindranath
authors.forename: J
authors.initials: J
authors.lastname: Krischer
authors.forename: P
authors.initials: P
authors.lastname: Steuber
authors.forename: C
authors.initials: C
authors.lastname: Civin
authors.forename: M
authors.initials: M
authors.lastname: Gresik
authors.forename: T
authors.initials: T
authors.lastname: Vietti
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D003561:Cytarabine / Q000008:administration & dosage; D003630:Daunorubicin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D006801:Humans; D007223:Infant; D007951:Leukemia, Myeloid / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D011379:Prognosis; D012074:Remission Induction; D015996:Survival Rate; D013866:Thioguanine / Q000008:administration & dosage
chemical_list: D003561:Cytarabine; D013866:Thioguanine; D003630:Daunorubicin